Cochrane · systematic review · CD003336
Anticoagulation versus placebo for heart failure in sinus rhythm
Shantsila, E, Kozieł, M, Lip, GYH · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
HeartAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
5
No studies
1
Included studies
NR
No studies 1 · 16.7%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 33.3%Moderate 2 · 33.3%High 1 · 16.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Warfarin compared to placebo or no treatment in people with chronic heart failure in sinus rhythm
Population: people with heart failure in sinus rhythm
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause death Warfarin vs placebo or no treatment | OR 0.66 [0.36, 1.18] | 2 studies · 324 participants | Low Downgraded: imprecision, inconsistency |
Stroke Warfarin vs placebo or no treatment | no estimate extracted | NR | No studies |
Major bleeding eventsc Warfarin vs placebo or no treatment | OR 5.98 [1.71, 20.93] | 2 studies · 324 participants | Low Downgraded: imprecision, inconsistency |
Rivaroxaban compared to placebo in people with heart failure in sinus rhythm
Population: people with heart failure in sinus rhythm
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause death Rivaroxaban vs placebo | OR 0.99 [0.87, 1.13] | 1 study · 5022 participants | High |
Stroke Rivaroxaban vs placebo | OR 0.67 [0.47, 0.95] | 1 study · 5022 participants | Moderate Downgraded: imprecision |
Major bleeding eventsb Rivaroxaban vs placebo | OR 1.65 [1.17, 2.33] | 1 study · 5008 participants | Moderate Downgraded: imprecision |